We are live on ! Find out more
ADIL icon

Adial Pharmaceuticals
ADIL

9 hedge funds and large institutions have $164K invested in Adial Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.98% less ownership

Funds ownership: 7.83% → 4.85% (-3%)

55% less funds holding

Funds holding: 20 → 9 (-11)

85% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 13

99% less capital inflows, than outflows

Capital inflows: $2.71K | Capital outflows: $183K

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
9
Holders Change
-11
Holders Change %
-55%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
2
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$2.6K
2
Abound Wealth Management
Abound Wealth Management
Tennessee
+$118

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$42.3K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$37.5K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$28.6K
4
Renaissance Technologies
Renaissance Technologies
New York
-$22K
5
State Street
State Street
Massachusetts
-$10.9K

ADIL Hedge Fund Activity: Q3 2023 in Review

9 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q3 2023, worth a combined $164K — down 66% from $488K a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of ADIL and 2 opened new positions — a net loss of 11 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was UBS Group, opening a new position worth an estimated $2.6K. The largest seller was Vanguard Group, exiting entirely with an estimated $42.3K sold.

  • 9 institutional investors held Adial Pharmaceuticals (ADIL) as of Q3 2023, down from 20 in Q2 2023.
  • Funds reported $164K of Adial Pharmaceuticals stock for Q3 2023, down 66% quarter-over-quarter.
  • 2 funds opened new Adial Pharmaceuticals positions in Q3 2023 and 13 closed out, a net change of -11 holders.
  • The largest Adial Pharmaceuticals buyer in Q3 2023 was UBS Group, an estimated $2.6K added.
  • The largest Adial Pharmaceuticals seller in Q3 2023 was Vanguard Group, an estimated $42.3K sold.

Based on aggregated 13F filings for Q3 2023.